Age, years | 51.0±13.7 |
Women | 195 (78%) |
White, non-Hispanic | 102 (40.8%) |
Hispanic | 73 (29.2%) |
Black | 56 (22.4%) |
Asian | 17 (6.8%) |
Multiethnic | 2 (0.8%) |
Formal education, years | 13 (12, 16) |
Duration of RA, years | 6.4 (2.2, 14.5) |
Seropositive | 188 (75.2%) |
Erosive | 141 (63.8%)† |
Swollen joint count (0–66) | 15 (9, 22) |
Swollen joint count (0–28) | 11 (7, 16) |
Tender joint count (0–68) | 22 (13, 35) |
Tender joint count (0–28) | 14 (8, 21) |
Physician global assessment (0–100) | 48.2±17.5 |
Erythrocyte sedimentation rate (mm/h) | 40±27 |
C-reactive protein (mg/L) | 7.4 (4.0, 19.5) |
Medications at entry | |
Methotrexate | 87 (35%) |
Hydroxychloroquine | 64 (25.7%) |
Sulfasalazine | 24 (9.6%) |
Leflunomide | 16 (6.4%) |
Prednisone | 88 (35%) |
Tumour necrosis factor-α inhibitors | 28 (11.2%) |
Other biologics | 2 (0.8%) |
Study treatment group | |
Dose escalation | 104 (41.6%) |
Prednisone initiation | 56 (22.4%) |
DMARD initiation | 90 (36%) |
* Plus–minus values are mean±SD. N (N, N) values are median (25th, 75th percentile). All other values are number (percentage)
† Of 221 patients with radiographs.
RA, rheumatoid arthritis.